|
|
| | 2H-Benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]- Basic information |
| | 2H-Benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]- Chemical Properties |
| density | 1.258±0.06 g/cm3(Predicted) | | pka | 10.73±0.30(Predicted) | | form | Solid | | color | White to off-white |
| | 2H-Benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]- Usage And Synthesis |
| Uses | GSK1034702 is a M1 mAChR allosteric agonist. GSK1034702 shows procognitive effects in rodents. GSK1034702 modulates hippocampal function to improve memory encoding in nicotine abstinence model of cognitive dysfunction[1]. | | References | [1] Bradley SJ, et al. Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Mol Pharmacol. 2018 Jun;93(6):645-656. DOI:10.1124/mol.118.111872 [2] Nathan PJ, et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013 May;16(4):721-31. DOI:10.1017/S1461145712000752 |
| | 2H-Benzimidazol-2-one, 4-fluoro-1,3-dihydro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]- Preparation Products And Raw materials |
|